Montelukast Sodium Granule
Product Images NDC 59651-329

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 59651-329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Montelukast Fig1)

The graph shows the change in height in centimeters over a period of 56 weeks for three different groups: a group taking Montelukast 5 mg (120 participants), a group taking Beclomethasone 336 mg (119 participants), and a group taking a placebo (121 participants). The x-axis represents the weeks on treatment and the y-axis represents the change in height in centimeters. However, the standard errors of the treatment group means in change in height are too small to be visible on the graph.*

FDA Label Image

Figure2 (Montelukast Fig2)

FDA Label Image

Package Label-principal Display Panel (4 mg (Packet))

This appears to be a combination of random and fragmented text that doesn't provide any coherent information or context. Hence, the text is not-available for generating a useful description.*

FDA Label Image

Package Label-principal Display Panel (4 mg (30 Packet Carton))

FDA Label Image

Chemical Structure (Montelukast Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.